Hypothesis

In aged bone marrow, hyperactive mTORC1 in niche macrophages actively suppresses autophagy, leading to accumulation of damaged mitochondria and elevated ROS. This oxidative environment modifies core autophagy proteins (e.g., LC3, ATG7) in adjacent erythroid progenitors, preventing lipidation and autophagosome formation even when EPO stimulates Akt/Erk1/2/BAD pathways. Consequently, EPO fails to induce protective autophagy, resulting in ineffective erythropoiesis and anemia despite high circulating EPO.

Mechanistic Rationale

• mTORC1 hyperactivation in senescent macrophages inhibits autophagosome formation via ULK1 phosphorylation [[https://doi.org/10.1016/j.exger.2014.11.004]].
• Impaired autophagy in macrophages causes mitochondrial dysfunction and ROS spillover [[https://pmc.ncbi.nlm.nih.gov/articles/PMC4058053/]].
• ROS can oxidize cysteine residues on LC3 and ATG3, blocking LC3‑II conjugation and autophagosome expansion—a mechanism not yet tested in erythroid progenitors [[https://pmc.ncbi.nlm.nih.gov/articles/PMC9527112/]].
• EPO‑triggered Akt/Erk1/2/BAD signaling normally promotes autophagy, but oxidative inhibition of the conjugation machinery uncouples this signal from functional autophagic flux.

Testable Predictions

1. Aged marrow macrophages will show higher p62 accumulation and lower LC3‑II/I ratios compared with young controls, indicative of suppressed autophagy.
2. ROS levels in the macrophage‑derived supernatant will correlate positively with oxidative modifications of LC3 in co‑cultured erythroid progenitors.
3. Pharmacological or genetic inhibition of mTORC1 specifically in macrophages will reduce ROS, restore LC3 lipidation in erythroid progenitors, and rescue EPO‑induced autophagy flux.
4. Restoring macrophage autophagy will improve erythroid burst‑forming unit (BFU‑E) colony formation and hemoglobinization in response to EPO, without directly altering HSC autophagy.

Experimental Approach

• Mouse models: Use young (3 mo) and aged (24 mo) C57BL/6 mice. Generate macrophage‑specific Raptor knockout (Raptor^fl/fl; LysM‑Cre) to inhibit mTORC1, and a control littermate group.
• Ex vivo assays: Isolate bone marrow macrophages and erythroid progenitors (CD71^+Ter119^−). Measure autophagy flux via LC3‑II turnover with bafilomycin A1, p62 levels, and mitochondrial ROS (MitoSOX). Detect oxidative LC3 modifications using biotin‑switch assays followed by Western blot.
• Co‑culture system: Place macrophages in transwell inserts above erythroid progenitors; add EPO (3 U/mL). Assess progenitor autophagy (LC3‑II/I), apoptosis (Annexin V), and erythroid differentiation (CD71/Ter119 flow cytometry, benzidine staining for hemoglobin).
• In vivo validation: Treat aged mice with macrophage-targeted rapamycin nanoparticle or vehicle for 2 weeks; monitor serum EPO, reticulocyte count, hemoglobin, and hematopoietic stress markers.

Potential Outcomes and Interpretation

• Support: Macrophage‑specific mTORC1 inhibition reduces niche ROS, restores LC3 lipidation in erythroid progenitors, enhances EPO‑induced autophagy, and improves anemia phenotypes. This would confirm that niche‑derived oxidative suppression, not HSC‑intrinsic autophagy failure, limits EPO efficacy.
• Refutation: If macrophage mTORC1 inhibition fails to alter ROS, LC3 oxidation, or erythroid progenitor autophagy/EPO response, the hypothesis is falsified, suggesting alternative mechanisms (e.g., direct HSC mTORC1 effects or cytokine-mediated autophagy blockade).

By linking niche macrophage metabolism to oxidative blockade of erythroid autophagy, this hypothesis provides a clear, falsifiable framework to explain why EPO therapy often falls short in older adults and identifies macrophage mTORC1 as a tractable target for restoring erythropoietic resilience in aging.